Monte Rosa Therapeutics, Inc.
GLUE • NASDAQ
Monte Rosa Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Markus Warmuth, with a market cap of $1.3B.
CEOMarkus Warmuth
Next Earnings
Upcoming earnings announcement for Monte Rosa Therapeutics, Inc.
Date
Thursday, May 7, 2026 (in 2 months)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.41
Revenue Estimate
$11.5M
Earnings History
Past 11 earnings reports for Monte Rosa Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 6, 2025 | Q3 2025 | -$0.33Est: -$0.37 | +10.8% | $12.8MEst: $7.5M | +69.5% |  10-Q |
| Aug 7, 2025 | Q2 2025 | -$0.15Est: -$0.34 | +55.9% | $23.2MEst: $8.7M | +167.3% | 10-Q |
| May 8, 2025 | Q1 2025 | $0.57Est: -$0.32 | +278.1% | $84.9MEst: $13.6M | +525.9% | 10-Q |
| Mar 20, 2025 | Q4 2024 | $0.23Est: -$0.37 | +162.2% | $60.6MEst: $12.8M | +374.2% | 10-K |
| Nov 7, 2024 | Q3 2024 | -$0.29Est: -$0.49 | +40.8% | $9.2MEst: $2.6M | +251.8% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.43Est: -$0.54 | +20.4% | $4.7MEst: $1.4M | +247.8% | — |
| May 9, 2024 | Q1 2024 | -$0.53Est: -$0.57 | +7.0% | $1.1MEst: $1.4M | -24.0% | 10-Q |
| Mar 14, 2024 | Q4 2023 | -$0.58Est: -$0.33 | -75.8% | -Est: $15.2M | -100.0% | 10-K |
| Nov 9, 2023 | Q3 2023 | -$0.70Est: -$0.72 | +2.8% | - | — | — |
| Aug 10, 2023 | Q2 2023 | -$0.71Est: -$0.70 | -1.4% | - | — | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.65Est: -$0.68 | +4.4% | - | — | 10-Q |